cisplatin， vinblastine， dacarbazine， interferon alfa， and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998；16：1752-1759. (ii) Eton O， Legha SS， Bedikian AY， et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma： results from a phase III randomized trial. J Clin Oncol 2002；20：2045-2052. (iii) O'Day SJ， Boasberg PD， Piro L， Kristedja TS， et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophagecolony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res. 2002(9)：2775-2781. (iv) Ives NJ， Stowe RL， Lorigan P， Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma： a metaanalysis of 18 trials involving 2，621 patients. J Clin Oncol 2007 25(34)：5426-5434. (v) Atkins MB， Hsu J， Lee S， et al. Phase III trial comparing concurrent biochemotherapy with cisplatin， vinblastine， dacarbazine， interleukin-2， and interferon alfa-2b with cisplatin， vinblastine， and dacarbazine alone in patients with metastatic malignant melanoma (E3695)： a trial coordinated by the eastern cooperative oncology group. J Clin Oncol 2008 Dec 10； 26(35)：5746-5754.
13、 (i) Rao RD， Holtan SG， Ingle JN， et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006；106(2)：375-382. (ii) Agarwala SS， Keilholz U， Hogg D， et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J Clin Oncol (Meeting Abstracts). 2007；25(18_suppl)：8510. (iii) Hauschild A， Agarwala SS， Trefzer U， et al. Results of a phase III， randomized， placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009；27：2823-2830. (iv) Flaherty KT， Lee SJ， Schuchter LM， et al. Final results of E2603： A double-blind， randomized phase III trial comparing carboplatin. (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. J Clin Oncol (ASCO Meeting Abstracts) 2010. 28：(suppl； abstr)：8511.
|
